Pfizer COVID-19 vaccine appointments are available to our patients. Sign up for Connect today to schedule your vaccination.

Perimenopause and Brain Aging in Alzheimer's Disease

Clinical Trial Details

The purpose of this study is to better identify and predict individuals at risk for Alzheimer's disease (AD) who are most likely to benefit from personalized, evidence-based interventions. Studies have shown that endocrine aging (menopause, perimenopause) increases Alzheimer’s disease risk specifically in women. Our goal is to unravel the biological mechanisms behind the increased risk by analyzing how various measures of brain function, biochemistry, laboratory values, and other risk factors may influence Alzheimer’s risk as women age. The ultimate goal of this research is to help characterize the optimal window of opportunity for therapeutic intervention in women at risk for Alzheimer’s.

Key Eligibility: 

Inclusion criteria: Individuals between the ages of 40-65, family history of Alzheimer’s disease, a diagnosis of normal cognition (no objective or subjective cognitive impairment) or a Subjective Cognitive Impairment as established by the Alzheimer’s Disease Neuroimaging Initiative cohort study (ADNI-2).

Exclusion criteria: Contraindication to MRI or PET, unstable medical conditions (e.g. unstable heart disease, unmanaged diabetes, cancer), any primary CNS diseases or illnesses, alcohol abuse, taking certain medications (e.g. benzodiazepines, cholinesterase inhibitors, psychostimulants, cancer chemotherapy, etc.). Women with thyroid disease will also be excluded.

Detailed eligibility will be reviewed when you contact the study team.

Study contact by location

Upper East Side - Manhattan


Eva Schelbaum
(646) 962-3557

Primary Investigator(s)

Protocol ID(s)

Weill Cornell Medicine IRB #:



Open to Enrollment

Age Group